Pharmacoeconomic considerations in treating patients with acute leukaemia

PharmacoEconomics

Volumn 15, Issue 2, 1999, Pages 167-178

  Jønsson, Viggo ^a,d   Hansen, Mogen Mørk ^a   Ljungman, Per ^b   Kaasa, Stein ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d Department of Haematology L 4042 ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTILEUKEMIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; VINCRISTINE;

ACUTE LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; DRUG COST; HEALTH CARE COST; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; ECONOMICS, PHARMACEUTICAL; HUMANS; LEUKEMIA;

EID: 0032940922     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915020-00005     Document Type: Review

References (48)

1. 1. Williams C, Coyle D, Gray A, et al. European School of Oncology advisory report to the Commission of the European Communities for the 'Europe Against Cancer Programme': cost-effectiveness in cancer care. Eur J Cancer 1995; 31: 1410-24
2. 2. Drummond MF. Cost-effectiveness guidelines for reimbursment of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Econ 1992; 1: 85-92
3. 3. Jönsson B, Karlsson G. Economic evaluation of cancer treatments. In: Williams CJ, editor. Introducing new treatments for cancer: practical, ethical and legal problems. New York (NY): John Wiley & Son, 1992: 237-65
4. 4. Kinney MC, Lukens JN. Classification and differentiation of the acute leukemias. In: Lee RG, Foerster J, Lukens J, et al., editors. Winthrobe's clinical hematology. Baltimore (MD): Williams & Wilkins, 1998: 2209-40
5. 5. Greer JP, Bear MR, Kinney MC. Acute myelogenous leukemia. In: Lee GR, Foerster J, Lukens J, et al., editors. Wintrobe's clinical hematology. Baltimore (MD): Williams & Wilkins, 1998: 2272-319
6. 6. Whitlock JA, Gaynon PS. Acute lymphocytic leukemia. In: Lee GR, Foerster J, Lukens J, et al., editors. Wintrobe's clinical hematology. Baltimore (MD): Williams & Wilkins, 1998: 2241-71
7. 7. Heil G, Mitrou PS, Hoelzer D, et al. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia: long-term follow-up of a prospective multicenter trial. Ann Hematol 1995; 71: 219-25
8. 8. Zhang MJ, Hoelzer D, Horowitz MM, et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation: the acute lymphoblastic leukemia working committee. Ann Intern Med 1995; 123: 428-31
9. 9. Hann IM, Stevens RF, Goldstone AH, Adult and Childhood Leukaemia Working Parties of the Medical Research Council, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia: results of the Medical Research Council's 10th AML trial (MRC AML 10). Blood 1997; 89: 2311-8
10. 10. Rohatiner AZS, Lister TA. Leukaemia. In: Cavalli F, Hansen HH, Kaye SB, editors. Textbook of medical oncology. London: Martin Dunitz Publishers, 1997: 243-63
11. 11. Klastersky J. Therapy of infections in cancer patients. In: Klastersky J, Schimpff SC, Senn HJ, editors. Handbook of suportive care in cancer. New York (NY): Marcel Dekker, 1995: 1-44
12. 12. Hughes WT, Armstrong D, Bodey GP, et al. Consensus report: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25: 551-73
13. 13. Viscoli C, Castagnola E. Planned progressive antimicrobial therapy in neutropenic patients. Br J Haematol 1998; 102: 879-88
14. 14. Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the Eroupean Organisation for Research and Treatment of Cancer, Leukemia Cooperative Group. J Clin Oncol 1996; 14: 2150-9
15. 15. Geissler K, Koller E, Huhmann E, et al. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia: a randomized phase III study. Blood 1997; 90: 590-6
16. 16. Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute mycloid leukemia. Blood 1997; 90: 2952-61
17. 17. Schmiegelow K, Ifersen M. Myelo- and hepatotoxicity, pharmacokinetics and relapse rate with methotrexate and 6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1996; 13: 433-41
18. 18. Sagmeister M, Gessner U, Horisberger B. Assessment of the cost of a febril neutropenic event in chemotherapy as a basis for socio-economic evaluation of a new cancer treatment. Int J Health Sci 1991; 2: 1-10
19. 19. Robinson R. Cost and cost-minimization analysis. BMJ 1993; 307: 726-8
20. 20. Robinson R. Cost-utility analysis. BMJ 1993; 307: 859-62
21. 21. Hoelzer D. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87: 495-508
22. 22. Bearman E. Use of stem cell factor to mobilize hematopoietic progenitors. Curr Opin Hematol 1997; 4: 163-70
23. 23. Mendelsohn ML. The growth fraction: a new concept applied to tumors. Science 1960; 132: 1496
24. 24. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of ponetial anticancer agents XIII, on the criteria and kinetics associated with curability of experimental leukaemia. Cancer Chemother Rep 1964; 35: 1-24
25. 25. Verweij J, Stoter G. Principles of systemic threapy of cancer. In: Cavalli F, Hansen HH, Kaye SA, editors. Textbook of medical oncology. London: Martin Dunitz, 1997; 23-40
26. 26. Bjordal K, Kaasa S, Mastekaasa A, et al. Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. Int J Radial Oncol Biol Phys 1994; 28: 847-56
27. 27. Hjermstad MJ, Kaasa S. Quality of life in adult cancer patients treated with bone marrow transplantation: a review of the literature. Eur J Cancer 1995; 31: 163-72
28. 28. Kaasa S, Bjordal K, Aaronson N, et al. The EORTC core quality of life questionnaire QLQ-C30: validity and reliability when analysed with patients treated with paliative radiotherapy. Eur J Cancer 1995; 31: 2260-3
29. 29. Torrance GW. Designing and conducting cost-utility analysis. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincolt-Raven Publishers, 1996: 1105-11
30. 30. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QIQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76
31. 31. Cella DF, Tulsky DS, Gray R, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-9
32. 32. Ware JE, Sherbourne CD. The MOS 36-item short form health status survey (SF-36): conceptual framework and item selection. Med Care 1992; 30: 473-83
33. 33. Hjermstad MJ, Fosså SD, Bjørndal K, et al. Test/retest for the European Organization for Research and Treatment of Cancer: Core Quality of Life Questionnaire. J Clin Oncol 1995; 13: 1249-54
34. 34. Ware JE, Bayliss MS, Kosinski M, et al. Comparison of methods for scoring and statistical analysis of the SF-36 health profile and summary measures. Mod Care 1995; 33: 264-79
35. 35. Lesourne J. Cost-benefit analysis and economic theory. In: Silvey A, editor. Studies in mathematical and managerial economics. Amsterdam: North-Holland Publishers, 1975: 1-521
36. 36. Williams CJ. Knowing just how effective is treatment: implications for care of cancer patients. Clin Oncol 1995; 7: 42-5
37. 37. Pashko S, Jacobs J, Santorsa J. The cost-effectiveness of idarubiein, cytosine arabinoside versus daunomycin, cytosine arabinoside in the treatment of adults with acute myeloid leukaemia. Clin Ther 1991; 13: 353-60
38. 38. Freund DA, Diltus RS. Double-blind, placebo-controlled trial of daunomycin and cytarabine with and without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpatient resource utilization. J Natl Cancer Inst Monogr 1995; 19: 37-40
39. 39. Rees JK, Gray RG, Wheatler K. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. Br J Haematol 1996; 94: 89-98
40. 40. Locatelli F, Zecca M, Pedrazzoli P, et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplanta. Bone Marrow Transplant 1994; 13: 403-1025
41. 41. Bennett CL, Golub R, Waters TM, et al. Economic analysis of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest 1997; 15: 227-36
42. 42. Barr R, Furlong W, Henwood J. et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol 1996; 14; 1413-20
43. 43. Phillips M, Richards S, Chessells J. Acute mycloid leukaemia in childhood: costs and benefits of intensive treatment. Br J Haematol 1991; 77: 473-7
44. 44. Stalfeldt AM, Brodin H. Cost over time in conventional treatment of acute myeloid leukaemia: a study exploring changes in treatment strategies over two decades. J Intern Med 1994; 236: 401-9
45. 45. Fayers PM, Hand DJ. Generalisation from phase III clinical trials: survival, quality of life, and health economics. Lancet 1997; 350: 1025-7
46. 46. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologeous bone marrow transplantation as consolidation after standard dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-43
47. 47. McGuire WP, Hoskins WJ, Braddy MF, et al. Cyclophosphamide and cisplation compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6
48. 48. Haller DG. An overview of adjuvant therapy for colorectal cancer. Eur J Cancer 1995; 31: 1255-63